Total PM sales from companies analyzed increased 14% over the same period last year with PM sales doubling over the past five years to represent 30% of total revenues
New York – Oct. 13, 2015 – Diaceutics Group today released a summary update to its Pharma Readiness for Personalized Medicine Report, which examines how prepared pharmaceutical companies are for the emerging personalized medicine business model.
The summary report specifically examined the revenue achievements and business shifts of fourteen top pharma companies over the course of 2015 compared with each of the last five years.
“With pharma pricing high on the news and political agenda we wanted to identify which parts of the pharma pipeline are seeing the highest revenue growth,” said Peter Keeling, CEO of Diaceutics Group. “I think the strong revenue numbers clearly show that targeted therapies, dependent upon an efficient diagnostic market, are on the rise and big pharma is at risk of losing significant share if they aren’t articulating the integrated healthcare value of diagnostic and therapy working together.
Based on pharma/diagnostic partnering or acquisition strategies alone, Roche is outpacing its competitors over the past three years with over thirty deals completed, twice as many as its nearest pharma rivals. “Our analysis suggests that more than any other pharma company operating in PM, Roche understands the importance of infrastructure investment to support commercialization of their PM pipeline,” said Keeling.
And that pipeline is increasingly dependent upon PM. The report also highlighted almost 75% of the late stage pipeline is either potentially associated with a known biomarker, biomarker strategy is pursued along with therapy development, or could benefit from PM strategy.
The Diaceutics report includes a comprehensive review and update of fourteen leading pharmaceutical companies with at least one targeted therapy on the market, and ranked them according to their potential to capitalize on opportunities in PM.
Methodology: The three-part analysis included a detailed quantitative and qualitative review of each company based on publicly available information, interviews with industry leaders, and an evaluation and company ranking derived from Diaceutics’ analysis of the data available on the fourteen companies. Company analysis included a review of corporate structure and leadership, R&D structure, phase III pipeline, management and marketing of existing therapies, business deals and strategic partnerships and communications. The 2010 to 2015 analysis uses three categories to rank the companies:
- “Disrupters” – companies which have demonstrated the ability to competitively reshape therapy areas via personalized medicine;
- “Breakaway” – companies that have made proactive investments positioning themselves to migrate operating models and corporate structure to successfully commercialize targeted therapies; and
- “Followers” – companies most likely to respond to the actions of others with little central PM management and little commercial experience with PM therapies.
Over the past twelve months, most companies have held their relative positions. However, Roche is increasing its commercial readiness lead over other Disruptor rivals Novartis and Janssen, and GSK and Sanofi fall further back into the Follower Category.
To access the summary report, click here.